中成药治疗阿尔茨海默病的系统评价与网状Meta分析
该研究通过网状Meta分析评价中成药与西药治疗阿尔茨海默病的疗效与安全性,检索7个数据库至2022年6月,最终纳入47项研究、涉及11种中成药。结果显示中成药在改善MMSE、ADL、有效率及ADAS-Cog方面优于口服西药,中成药联合西药效果尤为突出,且未显著增加不良反应风险。
要点
- 中成药联合西药在MMSE、ADL、有效率和ADAS-Cog排名第一。
- 中成药单用在减少不良反应方面排名第一。
- 结论需结合临床辨证论治,仍需大样本多中心高质量研究验证。
核心结论
- 中成药干预在改善MMSE、ADL、有效率和ADAS-Cog方面优于口服西药治疗,中成药联合西药效果尤为突出。
- 中成药干预未显著增加不良反应风险,中成药单用在减少不良反应方面排名第一。
研究设计与样本
- 研究为网状Meta分析,检索7个数据库,检索时间自各数据库建库至2022年6月。
- 最终纳入47项研究,涉及11种中成药。
主要发现
- 中成药联合西药与单用西药、单用中成药相比,在MMSE评分、ADL评分、有效率和ADAS-Cog评分上差异有统计学意义。
- 不良反应方面,中成药干预与单纯口服西药之间的差异有统计学意义。
- 排序概率分析显示中成药联合西药在MMSE、ADL、有效率和ADAS-Cog上排名第一。
临床怎么用
- 结论仍需结合临床辨证论治应用,并需更多大样本、多中心、高质量研究进一步验证。
局限性
- MMSE、ADL和有效率的漏斗图中多数研究对称分布于中线两侧,可能存在一定程度的小样本效应与发表偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to evaluate the efficacy and safety of Chinese patent medicine compared with western medicine in the treatment of Alzheimer's disease using the Network Meta-analysis. This study retrieved relevant studies from 7 databases, and the retrieval time was from the establishment of each database to June 2022. After the screening, data extraction, and quality assessment, 47 studies were finally analyzed, involving 11 Chinese patent medicines. The results demonstrated that Chinese patent medicine intervention was superior to oral western medicine treatment in improving the patient's condition as assessed by the Mini-mental State Examination (MMSE), Activities of Daily Living (ADL), effective rate, and Alzheimer's Disease Assessment Scale-Cognitive section (ADAS-Cog). Particularly, the effect of Chinese patent medicine combined with western medicine intervention was prominent. Meanwhile, Chinese patent medicine intervention in AD did not significantly increase the risk of adverse reactions. The results of the Network Meta-analysis demonstrated that Chinese patent medicine combined with western medicine had statistically significant differences in the MMSE score, ADL score, effective rate, and ADAS-Cog score, compared with both western medicine alone and Chinese patent medicine alone. In terms of adverse reactions, the difference between Chinese patent medicine intervention and simple oral western medicine was statistically significant. The results of further ranking probability analysis demonstrated that Chinese patent medicine combined with western medicine intervention ranked first in terms of MMSE, ADL, effective rate, and ADAS-Cog. Additionally, oral Chinese patent medicine intervention alone ranked first in reducing adverse reactions. In the funnel plots of the MMSE, ADL, and effective rate, most studies were symmetrically distributed on both sides of the midline, where small sample effects and publication bias might exist to some extent. However, this conclusion still needs to be combined with clinical syndrome differentiation and treatment, and more large-sample, multi-center, high-quality studies are needed for further verification.
引用
- Liu C, Zhang L, Li Y, et al. Traditional Chinese Patent Medicine in the Treatment of Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. Am J Chin Med. 2023. PMID: 36866797. doi:10.1142/S0192415X2350026X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。